Literature DB >> 17525783

Opioid analgesia: perspectives on right use and utility.

Jane C Ballantyne1.   

Abstract

The ability of opioids to effectively and safely control acute and cancer pain has been one of several arguments used to support extending opioid treatment to patients with chronic pain, against a backdrop of considerable caution that has been based upon fears of addiction. Of course, opioids may cause addiction, but the "principle of balance" may justify that "...efforts to address abuse should not interfere with legitimate medical practice and patient care." Yet, situations are increasingly encountered in which opioid-maintained patients are refractory to analgesia during periods of pain, or even during the course of chronic treatment. The real question is whether analgesic efficacy of opioids can be maintained over time. Overall, the evidence supporting long-term analgesic efficacy is weak. The putative mechanisms for failed opioid analgesia may be related to tolerance or opioid-induced hyperalgesia. Advances in basic sciences may help in understanding these phenomena, but the question of whether long-term opioid treatment can improve patients' function or quality of life remains a broader issue. Opioid side effects are well known, but with chronic use, most (except constipation) subside. Still, side effects can negatively affect the outcomes and continuity of therapy. This paper addresses 1) what evidence supports the long-term utility of opioids for chronic pain; 2) how side effects may alter quality of life; 3) the nature of addiction and why it is different in pain patients, and 4) on what grounds could pain medication be denied? These questions are discussed in light of patients' rights, and warrant balancing particular responsibilities with risks. These are framed within the Hippocratic tradition of "producing good for the patient and protecting from harm," so as to enable 1) more informed clinical decision making, and 2) progress towards right use and utility of opioid treatment for chronic pain.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17525783

Source DB:  PubMed          Journal:  Pain Physician        ISSN: 1533-3159            Impact factor:   4.965


  39 in total

1.  Novel κ-opioid receptor agonist MB-1C-OH produces potent analgesia with less depression and sedation.

Authors:  Le-sha Zhang; Jun Wang; Jian-chun Chen; Yi-min Tao; Yu-hua Wang; Xue-jun Xu; Jie Chen; Yun-gen Xu; Tao Xi; Xiao-wu Hu; Yu-jun Wang; Jing-gen Liu
Journal:  Acta Pharmacol Sin       Date:  2015-03-30       Impact factor: 6.150

Review 2.  Dependence and addiction during chronic opioid therapy.

Authors:  David N Juurlink; Irfan A Dhalla
Journal:  J Med Toxicol       Date:  2012-12

3.  Prescription drug monitoring program inquiry in psychiatric assessment: detection of high rates of opioid prescribing to a dual diagnosis population.

Authors:  Daniel T Hackman; Marion S Greene; Taya J Fernandes; Ashley M Brown; Eric R Wright; R Andrew Chambers
Journal:  J Clin Psychiatry       Date:  2014-07       Impact factor: 4.384

4.  Opioid prescriptions for chronic pain and overdose: a cohort study.

Authors:  Kate M Dunn; Kathleen W Saunders; Carolyn M Rutter; Caleb J Banta-Green; Joseph O Merrill; Mark D Sullivan; Constance M Weisner; Michael J Silverberg; Cynthia I Campbell; Bruce M Psaty; Michael Von Korff
Journal:  Ann Intern Med       Date:  2010-01-19       Impact factor: 25.391

5.  An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(R) hydromorphone in patients with chronic cancer pain.

Authors:  Magdi Hanna; Alberto Tuca; John Thipphawong
Journal:  BMC Palliat Care       Date:  2009-09-15       Impact factor: 3.234

6.  Designing an automated clinical decision support system to match clinical practice guidelines for opioid therapy for chronic pain.

Authors:  Jodie A Trafton; Susana B Martins; Martha C Michel; Dan Wang; Samson W Tu; David J Clark; Jan Elliott; Brigit Vucic; Steve Balt; Michael E Clark; Charles D Sintek; Jack Rosenberg; Denise Daniels; Mary K Goldstein
Journal:  Implement Sci       Date:  2010-04-12       Impact factor: 7.327

7.  Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials.

Authors:  Oliver Löwenstein; Petra Leyendecker; Eberhard A Lux; Mark Blagden; Karen H Simpson; Michael Hopp; Björn Bosse; Karen Reimer
Journal:  BMC Clin Pharmacol       Date:  2010-09-29

8.  Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain.

Authors:  A Sandner-Kiesling; P Leyendecker; M Hopp; L Tarau; J Lejcko; W Meissner; P Sevcik; M Hakl; R Hrib; R Uhl; H Dürr; K Reimer
Journal:  Int J Clin Pract       Date:  2010-03-29       Impact factor: 2.503

9.  Pain treatment with high-dose, controlled-release oxycodone: an Italian perspective.

Authors:  Fabio Ferrarese; Gioia Becchimanzi; Massimo Bernardo; Maria Anna Conte; Angela Gioia; Davide Ottaviani; Rosa Palomba; Gianfranco Pedelini; Laura Rigotti; Elvira Scelzi
Journal:  Ther Clin Risk Manag       Date:  2008-08       Impact factor: 2.423

10.  Challenges in using opioids to treat pain in persons with substance use disorders.

Authors:  Seddon R Savage; Kenneth L Kirsh; Steven D Passik
Journal:  Addict Sci Clin Pract       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.